Cargando…
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues
[Image: see text] ONC201 is a first-in-class imipridone molecule currently in clinical trials for the treatment of multiple cancers. Despite enormous clinical potential, the mechanism of action is controversial. To investigate the mechanism of ONC201 and identify compounds with improved potency, we...
Autores principales: | Graves, Paul R., Aponte-Collazo, Lucas J., Fennell, Emily M. J., Graves, Adam C., Hale, Andrew E., Dicheva, Nedyalka, Herring, Laura E., Gilbert, Thomas S. K., East, Michael P., McDonald, Ian M., Lockett, Matthew R., Ashamalla, Hani, Moorman, Nathaniel J., Karanewsky, Donald S., Iwanowicz, Edwin J., Holmuhamedov, Ekhson, Graves, Lee M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528275/ https://www.ncbi.nlm.nih.gov/pubmed/31021596 http://dx.doi.org/10.1021/acschembio.9b00222 |
Ejemplares similares
-
Correction to
“Mitochondrial Protease ClpP
Is a Target for the Anticancer Compounds ONC201 and Related Analogues”
por: Graves, Paul R., et al.
Publicado: (2022) -
Characterization of TR‐107, a novel chemical activator of the human mitochondrial protease ClpP
por: Fennell, Emily M. J., et al.
Publicado: (2022) -
The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021) -
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
por: Fennell, Emily M. J., et al.
Publicado: (2023) -
Assembly and proteolytic processing of mycobacterial ClpP1 and ClpP2
por: Benaroudj, Nadia, et al.
Publicado: (2011)